Corporate Support
Sitemap

Features

Customer Services

Events

Terms of Use

Singapore
Malaysia

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,234.6
-19.4 (-0.60%)

 

  • STI Straits Times Index
    3,234.6
    -19.4 (-0.60%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,574.4
    -3.5 (-0.22%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    27,909.1
    -431.9 (-1.52%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,976.5
    -84.2 (-2.75%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    23,795.4
    -235.9 (-0.98%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,249.2
    15.8 (0.25%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,246.1
    -21.1 (-0.93%)
    Index delayed 20 minutes
  • XAO XAO
    7,199.0
    -50.0 (-0.69%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,734.1M
  • Value: 1,390.5M
  • Rise: 93
  • Fall: 228
  • Unch: 497

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol

  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Reenova Investment^0.003+0.001
Medtecs Intl0.105+0.007
Ntegrator Intl0.015-
Golden Agri-Res0.225-0.005
Rex Intl0.174-0.014
AusGroup^0.039-0.005
YZJ Shipbldg SGD1.060-0.030
OEL0.024-0.005
Singtel3.340+0.060
Jiutian Chemical0.021-0.001

World Indices

World Indices
Name Last Change
Nasdaq 9,383.8 +13.0
HSI 27,909.1 -431.9
HSCEI 10,952.2 -222.5
Jakarta 6,249.2 +15.8
Nikkei 225 23,795.4 -235.9
SSE Comp 2,976.5 -84.2
Shanghai A 3,118.9 -88.2
Shanghai B 248.6 -8.9
PSE Comp 0.0
KOSPI 2,246.1 -21.1

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help

  • Factsheet

  • Print

BEIGENE BEIGENE
Quotes 15 Minutes Delayed. Updated at 23 Jan 2020 16:08
Last (HKD): 101.500 Change: -0.500 High: 102.000 Remarks: -
Change (%): -0.49 Low: 99.700
Open 102.000 Yesterday's Close 102.000
Buy Price 101.500 Sell Price 101.500
Buy Volume ('000) 2.6 Sell Volume ('000) 2.7
Cumulative Volume ('000) 67.9 Cumulative Value 6,824,595
 
Click to show Stock Prices chart

Key Statistics

EPS (HKD) a -5.27173 Trailing EPS (HKD) e -6.48183 NAV (HKD) b 10.0055
PE a - Trailing PE f - Price / NAV b 10.1444
Dividend (HKD) d - Cash In Hand (HKD) g 6.8120 Issued & Paid-up Shares c 1,001,700,000
Dividend Yield (%) d - Price / Cash In Hand g 14.900 Treasury Shares h -
Beta - 75 Daysi 0.328 R-Squared - 75 Days(%)i 0.25 Market Cap (M) 101,672.550
Beta - 500 Daysi 1.051 R-Squared - 500 Days (%)i 12.01 Enterprise Value (M) 94,262.577
Piotroski F Score 2 Exchange Code 6160 Par Value ( USD ) 0.00010
52 Weeks Volatility (%) 47.75 6-Month VWAP 100.599 Free Float (%) 71.0
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 06 Jan 2020.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 02 Aug 2018.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference BEIGENE HKEx 101,672.550 - - 10.1444 -
Industry Biotechnology HKEx 48,020.666 14.774 15.780 6.3203 2.473
Local Peer AMGEN-T HKEx 594,184.000 9.032 9.399 6.9364 4.385
Local Peer SINO BIOPHARM HKEx 144,849.829 13.518 14.030 4.3138 0.635
Local Peer WUXI BIO HKEx 131,263.877 175.744 137.391 13.5119 -
Local Peer GENSCRIPT BIO HKEx 32,753.258 196.970 - 9.2365 -
Local Peer 3SBIO HKEx 27,533.275 18.201 22.153 2.7137 -
Local Peer ALPHAMAB-B HKEx 12,934.908 - - -36.2976 -
Local Peer HAOHAI BIOTEC HKEx 12,717.994 25.902 28.707 2.9944 0.818
Local Peer FRONTAGE HKEx 8,652.928 98.222 98.215 4.4784 -
Local Peer CKLIFE SCIENCES HKEx 8,169.409 31.067 31.024 1.9567 1.176
Local Peer VIVA BIOTECH HKEx 6,996.954 65.240 65.238 3.6325 -
Local Peer ASCENTAGE-B HKEx 5,619.325 - - -3.0429 -
Local Peer SINOMAB BIO-B HKEx 3,984.710 - - - -
Other Local Peers ASCLETIS-B (HKEx), ESSEX BIO-TECH (HKEx), LEE'S PHARM (HKEx), BBI LIFE SCI (HKEx), UNI-BIO GROUP (HKEx), CT ENTERPRISE (HKEx), BIOSINO BIO-TEC (HKEx), REGENT PACIFIC (HKEx), EXTRAWELL PHAR (HKEx), HAO WEN HLDGS (HKEx)
Global Peer AMGEN INC NASDAQ 140,673.062 16.759 17.438 12.8739 2.363
Global Peer CSL ASX 139,428.012 51.969 51.969 18.6323 0.864
Global Peer GILEAD SCIENCES INC NASDAQ 80,248.465 14.711 29.799 3.8948 3.642
Global Peer VERTEX PHARMACEUTICAL NASDAQ 60,329.961 28.778 28.142 11.4840 -
Global Peer BIOGEN INC NASDAQ 51,985.340 11.733 9.635 3.7143 -
Global Peer ILLUMINA INC NASDAQ 48,657.000 58.907 50.007 10.9612 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 39,432.125 16.132 18.390 3.7539 -
Global Peer AGILENT TECHNOLOGIES INC NYSE 27,956.794 88.471 26.103 5.8881 0.678
Global Peer ALEXION PHARMACEUTICAL INC NASDAQ 24,651.817 317.678 16.767 2.3779 -
Global Peer SEATTLE GENETICS INC NASDAQ 19,143.816 - - 10.7573 -
Other Global Peers INCYTE CORPORATION (NASDAQ), BIOMARIN PHARMACEUTICAL (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), EXACT SCIENCES CORP (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), 10X GENOMICS INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), BIONTECH SE SPON ADS EACH REP 1 ORD SHS (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), MODERNA INC (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), EXELIXIS INC (NASDAQ), REPLIGEN CORP (NASDAQ), BLUEBIRD BIO INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), Lonza (SGX), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), IMMUNOMEDICS INC (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), FIBROGEN INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), ALKERMES PLC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), NATERA INC (NASDAQ), ACCELERON PHARMA (NASDAQ), KODIAK SCIENCES INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), UNIQURE N.V. (NASDAQ), CHEMOCENTRYX INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), EPIZYME INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), SYNTHORX INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), XENCOR INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), ARVINAS INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), INSMED INC (NASDAQ), VIELA BIO INC (NASDAQ), REGENXBIO INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), ALECTOR INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), CORTEXYME INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), VERACYTE INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), TG THERAPEUTICS INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), NEXTCURE INC (NASDAQ), POLYNOVO LIMITED (ASX), NGM BIOPHARMACEUTICALS INC (NASDAQ), MYOVANT SCIENCES LTD (NYSE), ROCKET PHARMACEUTICALS INC (NASDAQ), OPKO HEALTH INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), MESOBLAST LTD (ASX), NANOSTRING TECHNOLOGIES INC (NASDAQ), AVITA MEDICAL LTD (ASX), RAPT THERAPEUTICS INC (NASDAQ), DERMIRA INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), AVITA MEDICAL LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), INTREXON CORP (NASDAQ), XBIOTECH INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), ACHILLION PHARMACEUTICALS INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), CYTOKINETICS INC (NASDAQ), KADMON HLDGS INC (NYSE), OMEROS CORP (NASDAQ), AVROBIO INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), NANTKWEST INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), IMMUNOGEN INC (NASDAQ), RETROPHIN INC (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), ARDELYX INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), MORPHIC HOLDING INC (NASDAQ), MACROGENICS INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), PROTHENA CORP PLC (NASDAQ), AGENUS INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), MERUS B V (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), BELLUS HEALTH INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), ARCUS BIOSCIENCES INC (NYSE), RIGEL PHARMACEUTICALS INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), ANAPTYSBIO INC (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), CABALETTA BIO INC (NASDAQ), COMPUGEN (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), PERSONALIS INC (NASDAQ), RECRO PHARMA INC (NASDAQ), PDL BIOPHARMA INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), IVERIC BIO INC (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), MINERVA NEUROSCIENCES INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), MEDICINOVA INC (NASDAQ), GERON CORP (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), NEXT SCIENCE LTD (ASX), KAMADA (NASDAQ), DPHARMA (Bursa), ADMA BIOLOGICS INC (NASDAQ), PFENEX INC (NYSE American), WAVE LIFE SCIENCES LTD (NASDAQ), LIMINAL BIOSCIENCES INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), TELIX PHARMACEUTIC (ASX), EVOFEM BIOSCIENCES INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), NANOVIRICIDES INC (NYSE American), JOUNCE THERAPEUTICS INC (NASDAQ), NOVAVAX INC (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), AFFIMED N V (NASDAQ), XOMA CORP (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), IMV INC (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), GLYCOMIMETICS INC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), ATHERSYS INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), CHIASMA INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), NEUREN PHARMACEUTICALS LTD (ASX), FORTRESS BIOTECH INC (NASDAQ), MONOPAR THERAPEUTICS INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), CONTRAFECT CORP (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), ARAVIVE INC (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), SAVARA INC (NASDAQ), VERASTEM INC (NASDAQ), RESAPP HEALTH LIMITED (ASX), AVALON GLOBOCARE CORP (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), PYC THERAPEUTICS LIMITED (ASX), CEL-SCI CORP (NYSE American), NEUROBO PHARMACEUTICALS INC (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), ENZO BIOCHEM INC (NYSE), CHIMERIX INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), LINEAGE CELL THERAPEUTICS INC (NYSE American), ADURO BIOTECH INC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), OTONOMY INC (NASDAQ), COHBAR INC (NASDAQ), 22ND CENTURY GROUP INC (NYSE American), PALATIN TECHNOLOGIES INC (NYSE American), BELLICUM PHARMACEUTICALS (NASDAQ), IMUGENE LIMITED (ASX), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), SESEN BIO INC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), SYNLOGIC INC (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), INFLARX N V (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), CYNATA THERAPEUTICS LTD (ASX), TREVENA INC (NASDAQ), ORGENESIS INC (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), IMMUTEP LTD (ASX), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), VACCINEX INC (NASDAQ), VERMILLION INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), EQUILLIUM INC (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), SYNTHETIC BIOLOGICS INC (NYSE American), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), ORTHOCELL LIMITED (ASX), SUNESIS PHARMACEUTICALS INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), CURIS INC (NASDAQ), INMUNE BIO INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), RESTORBIO INC (NASDAQ), ADVAXIS INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), ISORAY INC (NYSE American), ONCONOVA THERAPEUTICS INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), SOLIGENIX INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS (NASDAQ), ZAFGEN INC (NASDAQ), EVOGENE LTD (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), BIOTRON (ASX), INVEX THERAPEUTICS LTD NPV (ASX), SEELOS THERAPEUTICS INC (NASDAQ), CELLDEX THERAPEUTICS INC (NASDAQ), OCUGEN INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), BIOCARDIA INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), AEVI GENOMIC MEDIC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), ACTINOGEN MEDICAL LTD (ASX), PULMATRIX INCORPORATED (NASDAQ), KAZIA THERAPEUTICS LIMITED (ASX), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), ANTEOTECH LIMITED (ASX), OUTLOOK THERAPEUTICS INC (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), BIONOMICS LTD (ASX), MEMPHASYS LTD (ASX), TALI DIGITAL LIMITED (ASX), VAXART INC (NASDAQ), GENETIC TECHNOLOGIES (ASX), AETERNA ZENTARIS INC (NASDAQ), ARMATA PHARMACEUTICALS INC (NYSE American), SOPHIRIS BIO INC (NASDAQ), IBIO INC (NYSE American), SIERRA ONCOLOGY INC (NASDAQ), ATYR PHARMA INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), ORAGENICS INC (NYSE American), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), INDIA GLOBALIZATION CAPITAL INC (NYSE American), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), RHINOMED LIMITED (ASX), CCP TECHNOLOGIES LTD (ASX), BIO-PATH HOLDINGS INC (NASDAQ), ACTINIUM PHARMACEUTICALS INC (NYSE American), CO DIAGNOSTICS INC (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), PROTEOMICS INTL LABORATORIES LTD (ASX), CORREVIO PHARMA CORP (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), PRECIPIO INC (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), SENESTECH INC (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), IMMURON LIMITED (ASX), PATRYS LIMITED (ASX), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), CELLMID LIMITED (ASX), PRESCIENT THERAPEUTICS LIMITED (ASX), CONATUS PHARMACEUTICALS INC (NASDAQ), BIOCEPT INC (NASDAQ), TOCAGEN INC (NASDAQ), Suntar Eco-City^ (SGX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), REGENEUS LTD (ASX), TROVAGENE INC (NASDAQ), CYCLACEL PHARMA IN (NASDAQ), HOLISTA COLLTECH LIMITED (ASX), ACHIEVE LIFE SCIENCE INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED (ASX), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), ANATARA LIFESCIENCES LTD (ASX), CLEVELAND BIOLABS INC (NASDAQ), ADALTA LTD (ASX), SIENNA CANCER DIAGNOSTICS LTD (ASX), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), XENETIC BIOSCIENCES INC (NASDAQ), NOVABAY PHARMACEUTICALS INC (NYSE American), OPGEN INC (NASDAQ), PLUS THERAPEUTICS INC (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), AIM IMMUNOTECH INC (NYSE American), CAPRICOR THERAPEUTICS INC (NASDAQ), BENITEC BIOPHARMA LTD (ASX), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), AUSTRALIAN PRIMARY HEMP LTD (ASX), LIVING CELL TECHNOLOGIES (ASX), BENITEC BIOPHARMA LTD SPON ADS EA REPR 200 ORD SHS(POST SPLIT) (NASDAQ), BIOXYNE LIMITED (ASX), MEDIBIO LIMITED (ASX), QT Vascular (SGX), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), MGRC (Bursa), SPHERIX INC (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), SENECA BIOPHARMA INC (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), TBG DIAGNOSTICS LTD (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), NANOLLOSE LTD (ASX), AMPLIA THERAPEUTICS LTD (ASX), FACTOR THERAPEUTICS LIMITED (ASX), BPH ENERGY LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+1.400
+1.40 %
10 Days -+3.100
+3.15 %
20 Days --2.400
-2.31 %
Medium Term Return 3 Months -+21.300
+26.56 %
6 Months -+24.200
+31.31 %
1 Year -+19.850
+24.31 %
Annualised Return Annualised --
+24.31 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 69.500 - 132.000 Change From 1 Year Low +32.000 % Change From 1 Year Low (%) +46.04
Change From 1 Year High -30.500 % Change From 1 Year High (%) -23.11
2 Years Range 61.050 - 132.000 Change From 2 Years Low +40.450 % Change From 2 Years Low (%) +66.26
Change From 2 Years High -30.500 % Change From 2 Years High (%) -23.11
5 Years Range 61.050 - 132.000 Change From 5 Years Low +40.450 % Change From 5 Years Low (%) +66.26
Change From 5 Years High -30.500 % Change From 5 Years High (%) -23.11
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.

Historical Price Data

Date Open High Low Close Volume VWAP
23 Jan 2020 102.000 102.000 99.700 101.500 67,900 100.5095
22 Jan 2020 102.000 102.900 101.600 102.000 63,500 102.1480
21 Jan 2020 106.200 107.100 102.000 102.700 115,700 103.9398
20 Jan 2020 102.000 108.000 101.800 106.200 162,700 105.3325
17 Jan 2020 101.800 103.500 101.500 102.700 127,800 102.5933
16 Jan 2020 99.900 100.500 99.100 99.950 86,360 99.8326
15 Jan 2020 99.450 101.300 99.250 100.100 46,100 100.0948
14 Jan 2020 99.000 100.200 98.100 99.450 127,300 99.4008
13 Jan 2020 99.500 101.300 98.000 98.850 101,000 98.6358
10 Jan 2020 98.200 101.300 98.200 101.300 117,700 100.2562
09 Jan 2020 98.000 98.800 97.100 97.500 57,100 97.6062
08 Jan 2020 98.050 98.500 98.050 98.400 5,300 98.4377
07 Jan 2020 98.000 101.000 98.000 98.500 36,129 99.1854
06 Jan 2020 98.950 98.950 97.700 98.100 82,900 98.1316
03 Jan 2020 99.050 99.750 98.250 99.150 86,300 99.1619
02 Jan 2020 102.200 102.200 98.250 99.000 39,200 98.8949
31 Dec 2019 100.300 100.300 98.250 100.000 24,500 99.5139
30 Dec 2019 103.800 103.800 99.850 100.300 87,075 100.7358
27 Dec 2019 103.700 103.800 101.500 103.800 108,000 102.7035
24 Dec 2019 103.800 104.400 103.000 103.900 37,200 103.8099
23 Dec 2019 103.200 104.800 102.800 104.400 51,500 103.5499
20 Dec 2019 99.900 103.000 99.800 102.600 93,200 101.5953
Summary
Current 2 Weeks
(10 Jan 2020 to 23 Jan 2020)		 98.200 108.000 98.000 101.500 1,016,060 -
Previous 2 Weeks
(24 Dec 2019 to 09 Jan 2020)		 103.800 108.000 98.000 97.500 563,704 -
4 Weeks from
(26 Nov 2019 to 23 Dec 2019)		 126.300 126.300 98.000 104.400 1,564,181 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.